Alkermes Earnings Call: Growth, LUMRIZE and New Risks

Alkermes plc ((ALKS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Alkermes’ latest earnings call struck an optimistic tone, underscoring solid 2025 commercial execution, strong cash reserves, and a transformational move into sleep medicine via the Avadel acquisition. Management balanced this upbeat message with clear warnings about near‑term GAAP losses, higher expenses, and competitive uncertainty, but framed these as investments to unlock durable growth.

Robust 2025 Revenue and Proprietary Growth

Alkermes reported 2025 total revenue near $1.5 billion, powered by about $1.18 billion in proprietary product sales. That proprietary portfolio grew roughly 9% year over year, reinforcing the company’s transition toward a higher‑margin, own‑brand driven model.

Mixed but Resilient Key Product Performance

VIVITROL posted net sales of $467.9 million, up about 2%, while ARISTADA reached $370 million, growing roughly 7% despite maturing market dynamics. LIVIALI delivered the standout performance at $346.7 million, rising about 24% and signaling meaningful momentum in the depression franchise.

Strong Profitability and Cash Firepower

For 2025, GAAP net income was $241.7 million with EBITDA of $285.6 million and adjusted EBITDA of $394 million, showcasing solid underlying profitability. The year closed with approximately $1.3 billion in cash and investments, giving Alkermes ample financial flexibility for pipeline and business development.

Strategic Avadel Deal Expands Sleep Medicine Platform

Alkermes closed the acquisition of Avadel in February 2026, gaining sleep drug LUMRIZE and an established commercial team in narcolepsy. The company deployed about $775 million of cash and took on a $1.525 billion term loan, with LUMRIZE expected to add roughly $315–335 million in 2026 revenue.

LUMRIZE Builds Commercial Traction

LUMRIZE generated about $279 million in net sales during 2025, supported by around 3,500 patients on therapy, a roughly 40% increase versus 2024. Alkermes expects full‑year 2026 LUMRIZE revenue of $350–370 million and has already recorded about $33 million in sales in the first six weeks post‑close.

Ambitious 2026 Growth and Earnings Targets

Management guided 2026 total revenue to $1.73–1.84 billion, reflecting both proprietary portfolio expansion and the Avadel contribution. Adjusted EBITDA is projected at $370–410 million, reinforcing the message that core earnings power should remain strong even as accounting impacts weigh on GAAP results.

Breakthrough Status and Phase 3 for Elixorexant

Pipeline momentum was anchored by elixorexant, an orexin‑2 receptor agonist that received FDA Breakthrough Therapy designation for narcolepsy. Alkermes plans to launch the global Phase 3 “Brilliance” program this quarter, including three 12‑week randomized studies across NT1 and NT2 patients using the Maintenance of Wakefulness Test as the primary endpoint.

Broader Orexin Portfolio Advances

Two additional orexin candidates, ALKS 7,290 and ALKS 4,510, completed Phase 1 studies in healthy volunteers. The company intends to move ALKS 7,290 into Phase 1b and Phase 2 trials for ADHD and advance ALKS 4,510 into a Phase 2a trial targeting fatigue in conditions such as MS and Parkinson’s disease.

Rising R&D to Fund Late‑Stage Pipeline

R&D expenses rose from $245.3 million in 2024 to $324 million in 2025 and are guided higher to $445–485 million in 2026. Management linked this step‑up directly to the global Phase 3 program for elixorexant and the continued development of the broader orexin‑based portfolio.

Higher SG&A and Transaction‑Driven Costs

Selling, general and administrative expense climbed to $701.5 million in 2025 from $645.2 million in 2024 as Alkermes expanded commercial efforts. For 2026, SG&A is expected to rise further to $890–930 million, including roughly $50 million of transaction costs tied to integrating Avadel.

Inventory Step‑Up Weighs on Gross Margin

Purchase accounting around LUMRIZE inventory created an estimated $180 million fair value step‑up, with about $150 million to flow through cost of goods sold as units are sold in 2026. This drives COGS guidance of $365–385 million and will temporarily pressure reported gross margins and GAAP profitability.

Leverage and Interest Burden from Financing

The $1.525 billion term loan used to finance the Avadel deal, alongside the $775 million cash deployment, adds a new layer of financial leverage. Net interest expense is projected at $75–85 million in 2026, with amortization of acquired intangibles expected in the $95–105 million range.

GAAP Loss Despite Solid Operating Earnings

While adjusted EBITDA is guided solidly positive for 2026, Alkermes expects a GAAP net loss of $115–135 million. Management tied this swing primarily to non‑cash and one‑time acquisition‑related items, including inventory step‑up, amortization, and transaction costs.

Non‑Recurring Gross‑to‑Net Tailwinds

Investors were cautioned that 2025 results for VIVITROL and ARISTADA benefited from one‑time gross‑to‑net favorability of about $27 million and $14 million, respectively. These benefits are not expected to repeat, meaning underlying growth trajectories may look more modest when adjusted for this temporary boost.

Oxybate Market and Payer Risks

Management flagged uncertainty around pricing and access in the oxybate class, particularly as generic Xyrem entries expand and competitors approach key regulatory dates. While LUMRIZE currently enjoys strong payer access, Alkermes plans to monitor the second‑half environment closely for shifts in reimbursement or competitive pressure.

Potential VIVITROL Generic Competition in 2027

The company acknowledged that VIVITROL could face generic entry as early as 2027, introducing significant revenue risk. However, executives emphasized that the manufacturing complexity of long‑acting injectables makes potential competitive and supply outcomes difficult to predict.

Forward‑Looking Guidance and Outlook

For 2026, Alkermes guided proprietary net sales to $1.52–1.60 billion and manufacturing and royalty revenue to $210–240 million, supporting total revenue of $1.73–1.84 billion. The company projects adjusted EBITDA of $370–410 million, EBITDA of $60–90 million, and a GAAP net loss of $115–135 million, with first‑quarter guidance pointing to a modest but positive adjusted EBITDA start to the year.

Alkermes’ earnings call painted the picture of a company leaning into growth, accepting short‑term accounting and expense headwinds to build a more diversified, higher‑value portfolio. For investors, the story now hinges on successful integration of LUMRIZE, execution of the orexin pipeline, and navigation of looming competitive and payer challenges across its key franchises.